MedTrace Logo

Pre-meals of 3-hydroxybutyrate in Type 2 Diabetes

NCT05581043 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-01-17

No results posted yet for this study

Summary

Hyperglycemia following meals in patients with type 2 diabetes mellitus (T2DM) is a common problem. Recently, our group found that oral consumption of the ketone metabolite, 3-hydroxybutyrate (3-OHB), effectively stimulates insulin secretion and delays gastric emptying.The aim of this study is to investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 20 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes)

Conditions

  • Ketosis
  • Postprandial Hyperglycemia
  • Glucose Metabolism Disorders (Including Diabetes Mellitus)

Interventions

DIETARY_SUPPLEMENT

3-hydroxybutyrate (3-OHB)

The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).

Sponsors & Collaborators

  • Steno Diabetes Center Aarhus, Aarhus University Hospital, Denmark

    collaborator UNKNOWN

  • Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark

    collaborator UNKNOWN

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Niels Møller, Professor · Professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-12
Primary Completion
2024-01-01
Completion
2024-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05581043 on ClinicalTrials.gov